ESTRO 2022 - Abstract Book

S1192

Abstract book

ESTRO 2022

Conclusion SBRT is a safe therapeutic approach in prostate cancer patients with an excellent tolerance and acute toxicity profile. Efficacy results will be reported once appropriate follow up is reached.

PO-1406 Hematological toxicity in pN1 prostate cancer patients treated with extended field irradiation

C. Berghen 1 , A. Laenen 2 , R. De Roover 3 , D. Dierickx 4 , S. Joniau 5 , K. Rans 1 , W. Crijns 1 , E. Baten 6 , H. Dumez 7 , W. Everaerts 5 , G. De Meerleer 1 1 University Hospitals Leuven, Department of Radiation Oncology, Leuven, Belgium; 2 Interuniversity Institute for Biostatistics Leuven, Department of Public Health & Primary Care, Leuven, Belgium; 3 University Hospitals of Leuven, Department of Radiation Oncology, Leuven, Belgium; 4 University Hospitals Leuven, Department of Hematology, Leuven, Belgium; 5 University Hospitals Leuven, Department of Urology, Leuven, Belgium; 6 General Regional Hospital Tienen, Department of Urology, Tienen, Belgium; 7 University Hospitals Leuven, Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, and Laboratory of experimental Oncology, Department of Oncology, Catholic University Leuven, Leuven, Belgium Purpose or Objective Adding whole pelvic radiotherapy (WPRT) to androgen deprivation therapy improves survival in patients diagnosed with pN1 prostate cancer (PCa). Enlarged treatment field with elective irradiation of the retroperitoneal lymph nodes may further improve outcome, as many of those patients already harbour micro metastases in the retroperitoneal lymph nodes. However, a larger irradiated volume of bone marrow (BM) can increase hematologic toxicity (HemT).